Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans
James Pritchett, Emma Harvey, Varinder Athwal, Andrew Berry, Cliff Rowe, Fiona Oakley, Anna Moles, Derek A. Mann, Nicoletta Bobola, Andrew D. Sharrocks, Brian J. Thomson, Abed M. Zaitoun, William L. Irving, Indra N. Guha, Neil A. Hanley, Karen Piper Hanley – 5 April 2012 – Osteopontin (OPN) is an important component of the extracellular matrix (ECM), which promotes liver fibrosis and has been described as a biomarker for its severity.